Skip to main content
Premium Trial:

Request an Annual Quote

Amgen to Use Illumina Genotyping Technology in Large Women's Health Study

NEW YORK (GenomeWeb News) — Illumina today said that Amgen will use its genotyping technology as part of a large women's health study. 
 
Under the agreement, Illumina will provide its HumanHap300-Duo BeadChip to Amgen, which will work with researchers at the Brigham and Women’s Hospital to genotype women who have been clinically tracked for a decade.
 
The research is part of the Women’s Genome Health Study, which follows 28,000 women in an effort to identify genetic variations to try to find genetic clues to illnesses such as heart disease, diabetes, breast cancer, osteoporosis, and others
 
Financial terms of the deal were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.